Grants paid by A Breath of Hope Lung Foundation
EIN 30-0475578 · Bloomington, MN · Form 990, Schedule I · NTEE G123
A Breath of Hope Lung Foundation of Bloomington, MN (EIN 30-0475578) reported 21 grants paid totaling $1,200,000 to 10 recipients in tax years 2018–2025, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$1,200,000
21 grants
Recipients
10
distinct organizations
Tax years
2018–2025
8 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 3 | $150,000 | — |
| 2019 | 2 | $150,000 | — |
| 2020 | 2 | $75,000 | — |
| 2021 | 2 | $150,000 | — |
| 2022 | 3 | $150,000 | — |
| 2023 | 1 | $75,000 | — |
| 2024 | 4 | $187,500 | — |
| 2025 | 4 | $262,500 | — |
Top recipients
The 10 recipients receiving the most from A Breath of Hope Lung Foundation, by grants paid, out of 10 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Mayo Clinic 41-6011702 | A | Rochester, MN | 2 | $150,000 | 2025 |
| Massachusetts Institute of Technology 04-2103594 | A | Cambridge, MA | 3 | $150,000 | 2020 |
| Massachusetts General Hospital 04-1564655 | A | Boston, MA | 3 | $150,000 | 2024 |
| University of Pittsburgh 25-0965591 | A | Pittsburgh, PA | 2 | $150,000 | 2019 |
| Whitehead Institute of Biomedical Research 60-1043412 | A | Cambridge, MA | 2 | $150,000 | 2022 |
| University of Texas Southwestern 75-6002868 | A | Dallas, TX | 3 | $150,000 | 2022 |
| Albert Einstein College of Medicine 83-0621846 | A | Bronx, NY | 2 | $112,500 | 2025 |
| Emory University 58-0566256 | A | Atlanta, GA | 2 | $112,500 | 2025 |
| University of Texas at Austin 74-6000203 | A | Austin, TX | 1 | $37,500 | 2025 |
| Nyu School of Medicine 13-3971298 | A | Boston, MA | 1 | $37,500 | 2018 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 21 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | Mayo Clinic Rochester, MN | A | $75,000 | paid | 2023 Peg's Fight for Life Award | 202621079349300837 |
| 2025 | Emory University Atlanta, GA | A | $75,000 | paid | 2024 Julie Swedberg YOLO Award | 202621079349300837 |
| 2025 | Albert Einstein College of Medicine Bronx, NY | A | $75,000 | paid | 2024 Peg's Fight for Life Award | 202621079349300837 |
| 2025 | University of Texas at Austin Austin, TX | A | $37,500 | paid | 2025 Peg's Fight for Life Award | 202621079349300837 |
| 2024 | Mayo Clinic Rochester, MN | A | $75,000 | paid | 2023 Peg's Fight for Life Award | 202501059349302800 |
| 2024 | Albert Einstein College of Medicine Bronx, NY | A | $37,500 | paid | 2024 Peg's Fight for Life Award | 202501059349302800 |
| 2024 | Emory University Atlanta, GA | A | $37,500 | paid | Julie Swedberg YOLO Award | 202501059349302800 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $37,500 | paid | 2022 Peg's Fight for Life Award | 202501059349302800 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $75,000 | paid | Pegs Fight for Life Award | 202431309349302208 |
| 2022 | Whitehead Inst for Biomedical Cambridge, MA | A | $75,000 | paid | Peg Fisher 2021 Research Award | 202341329349305689 |
| 2022 | Massachusetts General Boston, MA | A | $37,500 | paid | Pegs Fight for Life Award | 202341329349305689 |
| 2022 | Univ of Texas Sw Medical Dallas, TX | A | $37,500 | paid | Katherine Bensen Hope Award | 202341329349305689 |
| 2021 | Whitehead Institute of Biomedical Research Cambridge, MA | A | $75,000 | paid | This research project focuses on improving lung cancer outcomes with two aims: 1) To determine the mechanism by which macrophage activation enhances the response to EGFR TKIs; and 2: To investigate the anti-tumor efficacy of EGFR TKIs in combination with macrophage-directed therapies in xenograft models. | 202221229349301267 |
| 2021 | University of Texas Southwestern Dallas, TX | A | $75,000 | paid | The research project is seeking to understand the role of Telmerase that is expressed by most human cancers, particularly small cell lung cancer. We will target an essential survival mechanism of tumor cells to activate protective antitumor immunity and immune memory. We hypothesize that sytosolic DNA resulting from targeting telmerase with 6TdG treatment induces the cGAS/STING pathway, leading to enhanced antigen presentation and cyokine expression from tumors and dendritic cells (DC), causing the expansion and activation of tumor-specific T cells. If successful, our studies will guide the design of clinical trials. Given that NIH considers SCLC a recalcitrant disease, we believe SCLCs can easily be prioritized to be one of the first cancers to test 6TdG as these tumors do not have effective treatments currently. If we can generate strong preclinical evidence with this proposal, 6TdG can rapidly move in this subset in the clinic. | 202221229349301267 |
| 2020 | University of Texas Southwestern Dallas, TX | A | $37,500 | paid | The research project is seeking to understand the role of Telomerase that is expressed by most human cancers, particularly small cell lung cancer. We will target an essential survival mechanism of tumor cells to activate protective antitumor immunity and immune memory. We hypothesize that cytosolic DNA resulting from targeting telomerase with 6TdG treatment induces the cGAS/STING pathway, leading to enhanced antigen presentation and cytokine expression from tumors and dendritic cells (DC), causing the expansion and activation of tumor-specific T cells. If successful, our studies will guide the design of clinical trials. Given that NIH considers SCLC a recalcitrant disease, we believe SCLCs can easily be prioritized to be one of the first cancers to test 6TdG as these tumors do not have effective treatments currently. If we can generate strong preclinical evidence with this proposal, 6TdG can rapidly move in this subset in the clinic. | 202131119349301503 |
| 2020 | Massachusetts Institute of Technology Cambridge, MA | A | $37,500 | paid | The research project is seeking to tackle a long-standing question on whether the heterogeneity of a tumor is impacting its immune response. Although often perceived as one disease, any cancer lesion is comprised of millions of tumor cells. While some tumor cells seem similar to others, they may be very different in their appearance to the immune system. This phenomenon of high intra-tumor heterogeneity is particularly common in lung cancer. Despite us knowing about the heterogeneity, we currently have no mechanistic understanding of its impact on anti-tumor immunity. Understanding this interplay will help find rational and potent combination treatments with cancer immunotherapy, a relatively new treatment modality activating the patient's own immune system to fight cancer. | 202131119349301503 |
| 2019 | Massachusetts Institute of Technology Cambridge, MA | A | $75,000 | paid | Lung cancer research grant: The research project funded by A Breath of Hope Lung Foundation is seeking to tackle a long-standing question on whether the heterogeneity of a tumor is impacting its immune response. Although often perceived as one disease, any cancer lesion is comprised of millions of tumor cells. While some tumor cells seem similar to others, they may be very different in their appearance to the immune system. This phenomenon of high intra-tumor heterogeneity is particularly common in lung cancer. Despite us knowing about the heterogeneity, we currently have no mechanistic understanding about its impact on anti-tumor immunity. Understanding this interplay will help find rational and potent combination treatments with cancer immunotherapy, a relatively new treatment modality activating the patients' own immune system to fight cancer. | 202001419349301465 |
| 2019 | University of Pittsburgh Pittsburgh, PA | A | $75,000 | paid | Lung cancer research grant: Lung cancer is the leading cause of cancer death in women, killing more women each year than breast, uterine and ovarian cancers combined. Sex differences in non-small cell lung cancer (NSCLC) and survival suggest that estrogen plays a critical factor in the formation of tumors in women's lungs. Preclinical and epidemiological studies have demonstrated that the estrogen pathway is a driver of NSCLC progression in women. Results of this project will provide a mechanistic understanding of the role of estrogen on immune suppression and whether hormonal blockade can improve the response rate or durability of response in women with this type of cancer that are treated with targeted immunotherapy. | 202001419349301465 |
| 2018 | University of Pittsburgh Pittsburgh, PA | A | $75,000 | paid | Lung cancer research | 201921359349314512 |
| 2018 | Nyu School of Medicine Boston, MA | A | $37,500 | paid | Lung cancer research | 201921359349314512 |
| 2018 | Massachusetts Institute of Technology Cambridge, MA | A | $37,500 | paid | Lung cancer research | 201921359349314512 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2025 | 2025-12-31 | not stated | 2025v4.1 | 202621079349300837 |
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.0 | 202501059349302800 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202431309349302208 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202341329349305689 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.0 | 202221229349301267 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.0 | 202131119349301503 |
| 990 | 2019 | 2019-12-31 | not stated | 2019v5.0 | 202001419349301465 |
| 990 | 2018 | 2018-12-31 | not stated | 2018v3.0 | 201921359349314512 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/300475578.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.